http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022282330-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00ed0a5297e0d8268188852ac2a885c3 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6881 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6811 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6881 |
filingDate | 2020-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8482c942098de12af4ca3a36d0b6c363 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c2d223626bb72d2a8f11b308be1c14f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_108543e0a65b41b2cb8f93cf607c5767 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b099a2faa2409ea5abd39d96255a981 |
publicationDate | 2022-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2022282330-A1 |
titleOfInvention | Hla-h in medicine and diagnostics |
abstract | The present invention relates to a nucleic acid molecule, a vector, a host cell, or a protein or peptide, or combinations thereof for use as an immunosuppressant, as a tumor vaccine or as a pregnancy promoter wherein (I) the nucleic acid molecule is (a) encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; or (b) consisting of the nucleotide sequence of SEQ ID NO: 2; or (c) encoding a polypeptide which is at least 70%, preferably at least 80% identical, more preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of SEQ ID NO: 1; or (d) consisting of a nucleotide sequence which is at least 70% identical, preferably at least 80% identical, more preferably at least 90% identical, and most preferred at least 95% identical to the nucleotide sequence of SEQ ID NO: 2; or (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d); or (f) a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, and most preferably at least 600 nucleotides; or (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U; (II) the vector comprises the nucleic acid molecule of (I); (III) the host cell is transformed, transduced or transfected with the vector of (II); and (IV) the protein or peptide being encoded by the nucleic acid molecule of (I). |
priorityDate | 2019-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1151.